Clinical trial
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in…
NCT00469092 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00469092 |
|---|---|
| Title | Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes |
| Official title | A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin naïve Subjects With Type 2 Diabetes |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | biphasic insulin aspart, insulin glargine, metformin, glimepiride |
| Enrollment | 480 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 4, 2007 |
| Last update posted | Feb 23, 2017 |
| Countries | Argentina, Austria, Czechia, France, India, Malaysia, Mexico, Netherlands, Philippines, Poland, Romania, Serbia and Montenegro and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: